Research, symptoms, care, and policy developments related to long COVID and other post-viral illness.
A new randomized trial of remote, individualized, goal-focused cognitive rehabilitation for Long COVID brain fog found better “goal attainment” at 3 months—and the improvement persisted at 6 months. The benefits weren’t broad across all cognitive tests or every symptom, but they offer a practical model for function-focused rehab planning and for work accommodations planning in the U.S.
A July 2026 randomized trial found that goal-focused cognitive rehabilitation improved long COVID–related brain fog outcomes at 3 months—and the benefit was sustained at 6 months. The study is small and has limitations, so it’s best viewed as promising evidence. Here’s how to use this information to ask better questions about assessment, referrals (like OT/SLP), and ruling out other causes with a U.S. clinician.
An NIH-highlighted Cell study suggests that, in some people with long COVID, the immune system may react to nervous-system-related targets—pointing to possible biologic subgroups. But CDC guidance remains clear: in the U.S., long COVID is diagnosed clinically, and there is still no definitive lab test for routine use.
A new Cell study suggests that, for some people with Long COVID, the immune system may produce autoantibodies that recognize nervous-system targets—linked to specific neurological symptom patterns. But there’s still no routine blood test or proven, antibody-targeted treatment for everyday care.
A June 2026 RECOVER-ENERGIZE protocol shows researchers are no longer treating long COVID activity problems as one-size-fits-all. The trial separates people with post-exertional malaise from those without it, but the paper describes study design, not results.
A June 2026 trial found metformin missed its main test for preventing post-COVID symptoms, though a secondary clinician-diagnosed long-COVID signal was lower. CDC and IDSA still center vaccination and timely antiviral treatment for higher-risk patients.
A May 27, 2026 study suggests long COVID can be missed when health systems rely on diagnosis codes alone. Here is why estimates differ, what CDC says about diagnosis, and when to get checked.
A new randomized study suggests fluvoxamine may ease long COVID fatigue for some people, but the finding is narrow, early, and not enough to change routine care. CDC guidance still says long COVID is diagnosed clinically, there is no approved test, and treatment is focused on symptom management while research continues.
New CDC guidance and fresh research reinforce the same core message: long COVID can follow even a mild infection, normal tests do not rule it out, and the best proven way to lower risk is still reducing the chances of severe COVID-19. Early studies on fatigue treatments and supplements are interesting, but they are not yet practice-changing. New U.S. data also suggest long COVID still falls unevenly across communities, which matters for access to diagnosis and care.
CDC’s updated Long COVID guidance keeps the focus on symptoms, function, and follow-up care. The key takeaway for readers is simple: a normal lab workup does not automatically rule out Long COVID.
A COVID booster may still lower the chance of long COVID, but it is not a guarantee. The latest CDC guidance says vaccination remains the best available tool to prevent long COVID, while newer studies suggest protection that is real but not complete.
End of content
End of content
